As shown in Figure 3, following Ru-bdcurc treatment, cancer cells greatly increased the NRF2 protein levels and the expression of NRF2 targets, including HO-1, NQO1, and p62/SQSTM1 (Figure 3A–C), suggesting the induction of NRF2 transcriptional activity. The gene discussed is NFE2L2; the disease is cancer.